The spinal antinociceptive effect of FR140423 is mediated through kyotorphin receptors

Life Sciences

Volumn 66, Issue 23, 2000, Pages 2239-2245

  Ochi, Takehiro ^a   Motoyama, Yukio ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antinociception; FR140423; Kyotorphin receptors; Spinal cord

Indexed keywords

3 (DIFLUOROMETHYL) 1 (4 METHOXYPHENYL) 5 [4 (METHYLSULFINYL)PHENYL]PYRAZOLE; 3 (DIFLUOROMETHYL) 1 (4 METHOXYPHENYL) 5 [4(METHYLSULFINYL)PHENYL]PYRAZOLE; ENKEPHALIN; GUANYLATE CYCLASE; KYOTORPHIN; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NALTRINDOLE; OPIATE RECEPTOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; ENZYME ACTIVITY; PROSTAGLANDIN SYNTHESIS; SPINAL CORD;

EID: 0034724937     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00552-X     Document Type: Article

References (25)

1. T. Ochi, T. Fujii, Y. Motoyama and T. Goto, Jpn. J. Pharmacol. 81 94-98 (1999).
2. T. Ochi, K. Jobo-Magari, A. Yonezawa, K. Matsumori and T. Fujii, Eur. J. Pharmacol. 365 259-266 (1999).
3. K. Tsuji, N. Konishi, G. W. Spears, T. Ogino, K. Nakamura, T. Tojo, T. Ochi, F. Shimojo, H. Senoh and M. Matsuo, Chem. Pharm. Bull. 45 1475-1481 (1997).
4. T. Ochi, T. Fujii, Y. Motoyama and T. Goto, Eur. J. Pharmacol. 380 73-79 (1999).
5. A. Kawabata, Y. Nishimura and H. Takagi, Br. J. Pharmacol. 107 1096-1101 (1992).
6. A. Kawabata, S. Manabe and H. Takagi, Br. J. Pharmacol. 112 817-822 (1994).
7. H. Ueda, Y. Yoshihara, H. Misawa, N. Fukushima, T. Katada, M. Ui, H. Takagi and M. Satoh, J. Biol. Chem. 264 3732-3741 (1989).
8. S. Moncada, R. M. J. Palmer and E. A. Higgs, Biochem. Pharmacol. 38 1709-1715 (1989).
9. S. Moncada, R. M. J. Palmer and E. A. Higgs, Pharmacol. Rev. 43 109-142 (1991).
10. A. Kawabata, N. Umeda and H. Takagi, Br. J. Pharmacol. 109 73-79 (1993).
11. M. Zimmermann, Pain 16 109-110 (1983).
12. H. Takagi, T. Inukai and M. Nakama, Jpn. J. Pharmacol. 16 287-294 (1966).
13. J. L. K. Hylden and G. L. Wilcox, Eur. J. Pharmacol. 67 313-316 (1980).
14. T. J. Haley and W. G. McCormick, Br. J. Pharmacol. 12 12-15 (1957).
15. J. T. Litchefield Jr and F. Wilcoxon, J. Pharmacol. Exp. Ther. 96 99-113 (1949).
16. G. W. Pasternak, Clin. Neuropharmacol. 16 1-18 (1993).
17. P. J. Emmerson, M. Liu, J. H. Woods and F. Medzihradsky, J. Pharmacol. Exp. Ther. 271 1630-1637 (1994).
18. S. Kitabatake, R. Tsurutani, H. Nakajima, K. Tomita, Y. Yoshihara, H. Ueda, H. Takagi and K. Imahori, Pharmaceu. Res. 4 154-157 (1987).
19. H. Takagi, H. Shiomi, H. Ueda and H. Amano, Nature 282 410-412 (1979).
20. H. Shiomi, Y. Kuraishi, H. Ueda, Y. Harada, H. Amano and H. Takagi, Brain Res. 221 161-169 (1981).
21. H. Takagi, H. Shiomi, H. Ueda and H. Amano, Eur. J. Pharmacol. 55 109-111 (1979).
22. A. Kawabata, Y. Fukuzumi, Y. Fukushima and H. Takagi, Eur. J. Pharmacol. 218 153-158 (1992).
23. I. D. G. Duarte, B. B. Lorenzetti and S. H. Ferreira, Eur. J. Pharmacol. 186 289-293 (1990).
24. H. Takagi, Trends Pharmacol. Sci. 1 182-184 (1980).
25. Y. Kuraishi, Y. Harada and H. Takagi, Brain Res. 174 333-336 (1979).